Funda Meric‐Bernstam

Research interests

Publications

• Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2024.04.005

• Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

  Journal of Clinical Oncology · 2023 · 10.1200/jco.23.02005

• Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-022-02103-8

• Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00336-3

• First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

  Cancer Discovery · 2020 · https://doi.org/10.1158/2159-8290.cd-20-0868

• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.014

• KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1917239

• Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30904-5

• Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1714448

• Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

  Clinical Cancer Research · 2018 · https://doi.org/10.1158/1078-0432.ccr-18-2275

• Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.75.3780

• Targeting the PI3K pathway in cancer: are we making headway?

  Nature Reviews Clinical Oncology · 2018 · 10.1038/nrclinonc.2018.28

• HER kinase inhibition in patients with HER2- and HER3-mutant cancers

  Nature · 2018 · https://doi.org/10.1038/nature25475

• AACR Project GENIE: Powering Precision Medicine through an International Consortium

  Cancer Discovery · 2017 · https://doi.org/10.1158/2159-8290.cd-17-0151

• High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx004

• Punctuated copy number evolution and clonal stasis in triple-negative breast cancer

  Nature Genetics · 2016 · 10.1038/ng.3641

• Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.60.4165

• Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

  Clinical Cancer Research · 2014 · https://doi.org/10.1158/1078-0432.ccr-13-2332

• Clonal evolution in breast cancer revealed by single nucleus genome sequencing

  Nature · 2014 · 10.1038/nature13600

• PD-L1 Expression in Triple-Negative Breast Cancer

  Cancer Immunology Research · 2014 · https://doi.org/10.1158/2326-6066.cir-13-0127

• A pan-cancer proteomic perspective on The Cancer Genome Atlas

  Nature Communications · 2014 · 10.1038/ncomms4887

• Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

  Clinical Cancer Research · 2013 · https://doi.org/10.1158/1078-0432.ccr-13-0799

• Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-10-2560

• Targeting the mTOR Signaling Network for Cancer Therapy

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.20.0766

• Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.19.6410

• Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2008.16.7858

Current projects

No projects listed.